Setting sail: Atara raises $38.5m for Amgen spin-outs
This article was originally published in Scrip
Executive Summary
Atara Biotherapeutics raised $38.5m in a Series B venture capital round to launch its three drug development ships – the Nina, Pinta and Santa Maria – with drug candidates from Amgen for protein energy wasting associated with end-stage renal disease and ovarian cancer.